ABBV · Abbvie Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B |
| Cost of Revenue | $18.20B | $16.90B | $20.41B | $17.41B | $17.45B | $15.39B |
| Gross Profit | $42.96B | $39.43B | $33.90B | $40.64B | $38.75B | $30.42B |
| R&D | $9.10B | $12.79B | $7.67B | $6.51B | $7.08B | $6.56B |
| SG&A | $14.01B | $14.75B | $12.87B | $15.26B | $12.35B | $11.30B |
| Total Operating Expenses | $46.09B | $47.20B | $41.56B | $39.94B | $38.27B | $34.44B |
| D&A | $762.00M | $764.00M | $752.00M | $778.00M | $803.00M | $666.00M |
| Operating Income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B |
| Interest Expense | $2.89B | $2.81B | $2.22B | $2.23B | $2.42B | $2.45B |
| Income Tax | $2.36B | ($570.00M) | $1.38B | $1.63B | $1.44B | ($1.22B) |
| Net Income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B |
| EPS - Basic | $2.37 | $2.40 | $2.73 | $6.65 | $6.48 | $2.73 |
| EPS - Diluted | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.23B | $5.52B | $12.81B | $9.20B | $9.75B | $8.45B |
| Accounts Receivable | $12.59B | $10.92B | $11.15B | $11.25B | $9.98B | $8.82B |
| Inventory | $4.95B | $4.18B | $4.10B | $3.58B | $3.13B | $3.31B |
| Accounts Payable | $3.59B | $2.94B | $3.69B | $2.93B | $2.88B | $2.28B |
| Current Assets | $29.06B | $25.58B | $33.00B | $28.46B | $27.93B | $24.17B |
| Total Assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B |
| Current Liabilities | $43.29B | $38.75B | $37.84B | $29.54B | $35.19B | $28.66B |
| Long-term Debt | $64.50B | $66.84B | $59.24B | $63.13B | $75.96B | $84.95B |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | ($3.27B) | $3.33B | $10.36B | $17.25B | $15.41B | $13.08B |
| Retained Earnings | ($15.49B) | ($7.90B) | ($1.00B) | $4.78B | $3.13B | $1.05B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B | $17.59B |
| Investing Cash Flow | ($6.64B) | ($20.82B) | ($2.01B) | ($623.00M) | ($2.34B) | ($37.56B) |
| Financing Cash Flow | ($12.72B) | ($5.21B) | ($17.22B) | ($24.80B) | ($19.04B) | ($11.50B) |
| CapEx | $1.21B | $974.00M | $777.00M | $695.00M | $787.00M | $798.00M |
| Free Cash Flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B | $16.79B |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 70.2% | 70.0% | 62.4% | 70.0% | 69.0% | 66.4% |
| Operating margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% |
| EBITDA margin | 25.9% | 17.6% | 24.9% | 32.5% | 33.3% | 26.3% |
| Net margin | 6.9% | 7.6% | 9.0% | 20.4% | 20.5% | 10.1% |
| Free cash flow margin | 29.1% | 31.7% | 40.6% | 41.8% | 39.1% | 36.7% |
| FCF / Net income | 4.22 | 4.17 | 4.54 | 2.05 | 1.91 | 3.64 |
| R&D / Revenue | 14.9% | 22.7% | 14.1% | 11.2% | 12.6% | 14.3% |
| SG&A / Revenue | 22.9% | 26.2% | 23.7% | 26.3% | 22.0% | 24.7% |
| Effective tax rate | 35.9% | -15.4% | 22.1% | 12.1% | 11.1% | -36.1% |
| Return on assets | 3.2% | 3.2% | 3.6% | 8.5% | 7.9% | 3.1% |
| Return on equity | -129.2% | 128.7% | 46.9% | 68.6% | 74.9% | 35.3% |
| Return on invested capital | 15.8% | 13.0% | 14.3% | 19.8% | 17.4% | 11.6% |
| Liquidity | ||||||
| Current ratio | 0.67 | 0.66 | 0.87 | 0.96 | 0.79 | 0.84 |
| Quick ratio | 0.56 | 0.55 | 0.76 | 0.84 | 0.70 | 0.73 |
| Cash ratio | 0.12 | 0.14 | 0.34 | 0.31 | 0.28 | 0.29 |
| Leverage | ||||||
| Debt / Equity | -19.73 | 20.10 | 5.72 | 3.66 | 4.93 | 6.50 |
| Debt / Assets | 0.48 | 0.49 | 0.44 | 0.45 | 0.52 | 0.56 |
| Debt / EBITDA | 4.07 | 6.75 | 4.39 | 3.34 | 4.06 | 7.06 |
| Interest coverage | 5.2x | 3.3x | 5.7x | 8.1x | 7.4x | 4.6x |
| Equity multiplier | -40.97 | 40.65 | 13.00 | 8.04 | 9.51 | 11.51 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.46 | 0.42 | 0.40 | 0.42 | 0.38 | 0.30 |
| Inventory turnover | 3.68 | 4.04 | 4.98 | 4.87 | 5.58 | 4.65 |
| Days sales outstanding | 75d | 71d | 75d | 71d | 65d | 70d |
| Days inventory outstanding | 99d | 90d | 73d | 75d | 65d | 79d |
| Days payable outstanding | 72d | 64d | 66d | 61d | 60d | 54d |
| Cash conversion cycle | 102d | 97d | 82d | 84d | 70d | 95d |
| Valuation | ||||||
| P / E | 96.8x | 74.4x | 57.0x | 24.4x | 21.0x | 39.4x |
| P / B | - | 94.8x | 26.5x | 16.7x | 15.6x | 13.7x |
| P / S | 6.6x | 5.6x | 5.1x | 4.9x | 4.3x | 3.9x |
| EV / EBITDA | 29.3x | 38.0x | 23.8x | 18.1x | 16.4x | 21.3x |
| Growth | ||||||
| Revenue growth (YoY) | 8.6% | 3.7% | -6.4% | 3.3% | 22.7% | 37.7% |
| Revenue CAGR (3y) | 1.8% | 0.1% | 5.8% | 20.4% | 29.9% | 17.5% |
| Revenue CAGR (5y) | 6.0% | 11.1% | 16.2% | 15.5% | 17.0% | 14.9% |
| Gross profit growth (YoY) | 8.9% | 16.3% | -16.6% | 4.9% | 27.4% | 17.8% |
| Operating income growth (YoY) | 65.0% | -28.4% | -29.6% | 1.1% | 57.7% | -12.5% |
| Net income growth (YoY) | -1.2% | -12.0% | -58.9% | 2.5% | 150.0% | -41.4% |
| EPS growth (YoY) | -1.3% | -12.1% | -59.0% | 2.8% | 137.1% | -48.5% |
| EPS CAGR (3y) | -29.1% | -28.2% | 0.0% | 7.9% | 20.8% | -6.2% |
| EPS CAGR (5y) | -2.8% | -14.7% | -5.8% | 15.0% | 12.2% | -2.8% |
| FCF growth (YoY) | -0.1% | -19.2% | -9.0% | 10.3% | 31.0% | 78.5% |
| FCF CAGR (5y) | 1.2% | 13.6% | 11.5% | 20.8% | 27.4% | 19.1% |
| Book value growth (YoY) | - | -67.9% | -40.0% | 12.0% | 17.8% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$47.21B totalSKYRIZI$15.20B · 32.2%
RINVOQ$5.94B · 12.6%
Vraylar$3.61B · 7.7%
Botox Therapeutic$3.15B · 6.7%
HUMIRA$3.06B · 6.5%
Other Products$2.63B · 5.6%
Imbruvica$2.05B · 4.3%
Creon$1.51B · 3.2%
Botox Cosmetic$1.50B · 3.2%
VENCLEXTA$1.31B · 2.8%
Ubrelvy$1.24B · 2.6%
Other Aesthetics$1.10B · 2.3%
Qulipta$906.00M · 1.9%
Linzess Constella$864.00M · 1.8%
MAVYRET$635.00M · 1.3%
Elahere$607.00M · 1.3%
Other Eye Care$588.00M · 1.2%
Juvederm Collection$385.00M · 0.8%
Other Neuroscience$192.00M · 0.4%
Lumigan Ganfort$189.00M · 0.4%
Vyalev$167.00M · 0.4%
Ozurdex$124.00M · 0.3%
Epkinly$90.00M · 0.2%
Duodopa$73.00M · 0.2%
Alphagan Combigan$53.00M · 0.1%
Other Oncology$33.00M · 0.1%
Geographic
$61.16B totalUS$46.60B · 76.2%
Other Countries$5.76B · 9.4%
DE$1.74B · 2.8%
JP$1.27B · 2.1%
CA$1.22B · 2.0%
CN$1.01B · 1.6%
FR$806.00M · 1.3%
GB$626.00M · 1.0%
ES$609.00M · 1.0%
IT$580.00M · 0.9%
BR$478.00M · 0.8%
AU$459.00M · 0.8%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
8/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing AbbVie Inc. against the 5 most active filers in the same SIC group.
Dividends
$6.74/share trailing 12 months · +5.6% YoY
| Ex-date | Per share |
|---|---|
| Apr 15, 2026 | $1.7300 |
| Jan 16, 2026 | $1.7300 |
| Oct 15, 2025 | $1.6400 |
| Jul 15, 2025 | $1.6400 |
| Apr 15, 2025 | $1.6400 |
| Jan 15, 2025 | $1.6400 |
| Oct 15, 2024 | $1.5500 |
| Jul 15, 2024 | $1.5500 |
| Apr 12, 2024 | $1.5500 |
| Jan 12, 2024 | $1.5500 |
| Oct 12, 2023 | $1.4800 |
| Jul 13, 2023 | $1.4800 |
| Apr 13, 2023 | $1.4800 |
| Jan 12, 2023 | $1.4800 |
| Oct 13, 2022 | $1.4100 |
| Jul 14, 2022 | $1.4100 |
| Apr 13, 2022 | $1.4100 |
| Jan 13, 2022 | $1.4100 |
| Oct 14, 2021 | $1.3000 |
| Jul 14, 2021 | $1.3000 |
| Apr 14, 2021 | $1.3000 |
| Jan 14, 2021 | $1.3000 |
| Oct 14, 2020 | $1.1800 |
| Jul 14, 2020 | $1.1800 |